Worlds leading Nosocomial and Healthcare associated Infections Conference | America

Theme: Exploring the Challenges and Innovations in Outbreak Prevention and Control

NHAI 2017

NHAI 2017

We organize 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums on various topics of Science & Technology across the globe with support from 1000 more scientific societies and Publishes 500+ Open Access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

The organization feels proud and honoured in inviting the contributors across the globe to its premier World Summit on Nosocomial and Healthcare associated Infections to be held during October 02-04, 2017 at Las Vegas, USA.

Track 1: Hospital Infections

Hospital infections are one of the major complications for health care professionals to tackle. Every day they results in prolonged hospital stays, long-term disability, and increased resistance of microbes to antimicrobials, additional costs for healthcare systems, high costs for patients and their family, and unnecessary deaths.

Track 2: Device-Related Infections

Medical devices are responsible for a large proportion of nosocomial infections, mainly in critically ill patients. The infections associated with the devices can cause significant medical and economic sequela. The bacterial colonization of the indwelling device may be a prelude to both the infection and the malfunction of the device. The pathogenesis of the infections associated with the devices is centred on the multifaceted interaction of microbial, device and hosts factors.

Track 3: Surgical Site Infections

Surgical site Infection is a type of infection associated with healthcare in which a wound infection occurs after an invasive (surgical) procedure. They have a significant effect on the quality of life of the patient and are associated with significant morbidity and prolonged hospital stay. Further these infections result in considerable financial burden for health care providers.

Track 4: Urinary Tract Infections

A urinary tract infection is an infection relating to any part of the urinary system, including the urethra, bladder, ureters and kidneys. It is the most common type of hospital infection, among which urinary catheter infection is more frequent and caused by the urinary catheter, which is a tube inserted into the bladder through the urethra to drain the urine.

Track 5: Respiratory disorders and infections

Pneumonia contracted by a patient in a hospital at least 48-72 hours after admission is known as Nosocomial pneumonia and Pneumonia associated with health risk factors such as prior hospitalization, dialysis, residing in a nursing home, immunocompromised condition is classified as a health care-associated pneumonia.

Track 6: Blood Stream Infections

Blood Infections or Bacteraemia or Sepsis occurs when a bacterial infection occur somewhere else in the body such as in the lungs or skin which enters the blood stream. This is dangerous because bacteria and their toxins can be transported through the bloodstream to the entire body.

Track 7: Microbial Biofilms

Microbial biofilms develop when microorganisms irreversibly adhere to a submerged surface and produce extracellular polymers that facilitate adhesion and provide a structural matrix. The Surface may be an inert, non-living or living tissue. Microorganisms may originate from the skin of patients or health workers, from tap water to which ports of entry are exposed, or from other sources in the environment. To better understand and control biofilms on permanent medical devices, researchers must develop reliable sampling and measurement techniques, study the role of biofilms in antimicrobial resistance, and to establish the link between biofilm contamination and infection of the patient.

Track 8: Emerging Infectious Diseases

Emerging infectious diseases are caused by newly recognized species or strains (such as Severe Acute Respiratory Syndrome, HIV / AIDS) that may have evolved from a known infection (such as influenza) or spread to a new population (Such as West Nile fever) or undergoing ecological transformation (such as Lyme disease) or re-emerging infections, such as drug-resistant tuberculosis. Nosocomial infections caused by methicillin-resistant Staphylococcus aureus are emerging in hospitals and are extremely difficult to treat as they are resistant to many antibiotics. Many emerging diseases are zoonotic - an animal reservoir incubates the body with only intermittent transmission in human populations.

Track 9: Antibiotics and Antimicrobial Use

Antibiotics are one of the most important therapeutic discoveries in the history of medicine. They have revolutionized the way we treat patients with infections and help reduce mortality and morbidity. Unfortunately, antibiotics are more likely to be misused. They are often unnecessarily prescribed for viral infections, against which they have no effect. Not only antibiotics, other antivirals and antimicrobials are losing their effectiveness due to their irrational use and causing antimicrobial resistance.

Track 10: Microbial pathogenesis and Antimicrobial Resistance

Microbial Pathogenesis reviews about the molecular and cellular mechanisms of infectious diseases. It covers microbiology, host-pathogen interaction and immunology related to infectious agents. Antimicrobial resistance refers to the natural ability of microbes to evolve genetically to counter medications. The misuse of antibiotics leads to the appearance and selection of resistant bacteria. Now the whole world is facing situation where infected patients cannot be treated effectively because the responsible bacterium is totally resistant to the antibiotics available.

Track 11: Infection Prevention and Control

Infection control concerns the prevention of nosocomial and healthcare acquired infections. These infections are often caused by violations of infection control practices and procedures, contaminated and non-sterile surfaces or by sick hospital staff. It requires an integrated approach, a follow-up program that includes the following key elements as limiting the transmission of organisms between patients in direct patient care through hand washing and the use of appropriate gloves and aseptic practice, strategies for isolation, sterilization and disinfection practices, and nutrition and immunization, limiting the risk of endogenous infections minimizing invasive procedures and promoting optimal use of antimicrobials, infection surveillance, Identification and control of epidemics, prevention of infection among staff members, strengthening of patient care practices and continuous training of staff.

Track 12: Epidemiology and Public Health

Epidemiology is the "who, what, when, and where" of infectious diseases. The agents are transmitted through the air, food, insects, and some spread through person to person. Some agents occur worldwide, and others only in certain geographic areas or ecological circumstances. Every life form built its own profile vital. It is essential to discover the emergence of "new" diseases. Epidemiology helps develop the methodology to be used in clinical research studies, and to a lesser extent, basic research in the biological sciences. Epidemiological studies involve an introduction, all the historical background, sources of surveillance data, laboratory diagnosis, the biological characteristics of the organism, mechanisms and routes of transmission, pathogenesis and immunity response the host, and finally the prevention, control and treatment. Epidemiologists with the help of the study design, data collection and statistical analysis of data, as well as the interpretation and dissemination of results that include peer review and the occasional systematic review. In this, they help implement and evaluate interventions at individual and community level

To prevent infection (primary prevention)
To prevent the development of disease (secondary prevention) and also
To prevent death and disability (tertiary prevention) associated with the disease

Track 13: Opportunistic Infections

Opportunistic infection is an infection caused by pathogens like bacteria, viruses, fungi or protozoa that take advantage of an opportunity that is not normally available such as a host with a weakened immune system, a modified micro biota (like disturbed Intestinal flora) or violated the integumentary barriers. Many of these pathogens do not cause disease in a healthy host that is a normal immune system. However, a compromised immune system, penetrating injury or lack of competition from normal commensals presents an opportunity for the pathogen to infect.

Track 14: Therapeutic Approaches

Nosocomial infections are a major challenge for patient safety. Empirical antibiotic therapy should be based on thorough clinical evaluation and local epidemiological data on potential pathogens and susceptibility to antibiotics. The chosen therapy must be effective, limit the toxicity and be the narrowest spectrum possible. The choice of parenteral, oral or topical antibiotic formulations is made on the basis of clinical presentation (site and severity of infection).

Track 15: Vaccines and Immunization

A vaccine is a biological product that provides active acquired immunity to a particular disease

A vaccination is the injection of a killed or weakened organism that produces immunity against particular organism in the body.

Immunization is the process by which a person or animal is protected from disease. Vaccines cause immunization, and there are also some diseases that cause immunization after a person recovers from the disease.

Track 16: Diagnostic Mirobiology and Bioterrorism

Diagnostic microbiology plays a key role in individual and community health. Clinical microbiology laboratory which is a part of diagnostic microbiology plays essential role for the welfare of our people to analyse samples from patients and collecting data that allow the correct diagnosis to be made for victims of infectious diseases. They are sentinel events for bioterrorism and natural outbreaks of infection that threaten public health of the communities they serve. These laboratories provide vital information which guides the choice of antimicrobial therapy right for patients to infections that can be treated. They are the first to recognize the emergence of resistance to commonly used antimicrobial drugs. People working in clinical microbiology laboratories are highly trained professionals who make countless decisions every day that save lives and benefit the patients and at risk in our society.

Track 17: Occupational Health hazards and safety

Biological agents, including microorganisms and toxins produced by living organisms, can cause health problems in workers. Influenza is an example of a biohazard which affects a broad population of workers. Occupational illness results from exposure in a workplace to a physical, chemical or biological agent to the extent that the normal physiological mechanisms are affected and the health of the worker is impaired.

Track 18: Environmental Microbiology and Bioterrorism

Microbes are all over the world and in every possible environment. For example into the soil, one gram contains billions of microbes and all their related activities. Imagine the challenge to explore all the main groups of microbes found in each of the biomes of the earth given the scale of their immense diversity. So imagine the challenge of developing strategies to exploit and manipulate their activities. This is what environmental microbiology is about.

Track 19: Medical Microbiology

Medical microbiology deals with the body's response to the invasion of microorganisms. Bacteriology, virology, mycology, parasitology are the main areas of concern in medical microbiology. Microbial generations are intelligent enough to cause a change in their resistance patterns, paving the way for the development of new strategies and new trends in the fight against microbial infections. There has been a tremendous change in diagnostic methods and tools from the nucleic acid framework to circulate biomarker studies.

Track 20: Pharmaceutical Microbiology

Pharmaceutical Microbiology includes research and development of antibiotic resistance, anti-infective agents, the use of microorganisms to detect carcinogenic activity and mutagenic in scheduled drugs, as well as the use of microorganisms in the making pharmaceutical products such as human growth hormone and insulin. It also focuses on the safety of medicines and also determines how a product will react in cases of contamination.

Track 21: Clinical Studies and Case Reports

Clinical studies help invent new treatment methods that help provide effective treatment. Case reports on infectious diseases include research, biology, epidemiology and clinical aspects of all diseases related to infection.

Track 22: Health Care Professionals and Infections Specialists Meeting

Health professionals and specialists in the field of microbial infection control, prevention and treatment can exhibit their products and make presentations on their products and research that should be useful in research work, business development and marketing.

Track 23: Entrepreneurs Investment Meet

A platform designed to connect Entrepreneurs, Investors and Proposers worldwide. It aims to create and facilitate the most optimized and viable meeting place to engage people in global business discussions, evaluating and executing promising business ideas. An investor might be able to find the best potential investment opportunities globally, which provide a good return on investment. For entrepreneurs, it would be a great place to find investors and appropriate partners to start and expand their business. Thus, it is an ideal place to connect entrepreneurs, business owners, start-up companies and established companies with domestic or international investors, corporate investors and potential business partners.

Track 24: Global trends in Nosocomial and Healthcare Acquired Infections

The global hospital acquired infections testing market is poised to grow at a compound annual growth rate (CAGR) of around 19.1% over the next decade to reach approximately $2.75 billion by 2025.
The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.
Estimated cost of treating resistant infections in U.S. Health care system is about $21 billion to $34 billion annually.

Summary: NHAI 2017 welcomes attendees, presenters, and exhibitors from all over the world to Las Vegas, USA. We are delighted to invite you all to attend and register for the “International Congress on Nosocomial and Healthcare associated Infections” which is going to be held during October 02-04, 2017 at Las Vegas, USA. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the NHAI 2017, where you will be sure to have a meaningful experience with scholars from around the world. All the members of NHAI 2017 organizing committee look forward to meet you at Las Vegas, USA.

For more details, please visit: http://nosocomialinfections.conferenceseries.com/

Nosocomial infections (NI) or hospital acquired infections (HAI) are one of the major complications for health care professionals to tackle. Every day, NI results in prolonged hospital stays, long-term disability, and increased resistance of microorganisms to antimicrobials, massive additional costs for health systems, high costs for patients and their family, and unnecessary deaths. NI represents the most frequent adverse event during care delivery and no institution or country can claim to have solved the problem yet. Based on data from a number of countries, it can be estimated that each year, hundreds of millions of patients around the world are affected by NI.

Why Las Vegas, USA?

Las Vegas is the most populous city in Nevada, the seat of Clark County, and an internationally renowned major resort city for shopping and fine dining. Las Vegas, which bills itself as The Entertainment Capital of the World, is famous for the number of casino resorts and associated entertainment. A growing retirement and family city, it is the 28th most populous city in the United States.

The major attractions in Las Vegas are the casinos and the hotels. The most famous hotel casinos are located on Las Vegas Boulevard on the portion of that road known as the Las Vegas Strip. These larger casinos are located outside of the city. Many of these hotels are massive, providing thousands of rooms, with their large adjoining casino areas. There are many hotel casinos in the city's downtown area as well, which was the focal point of the city's gaming industry in its early days. Several large hotels and casinos are also located somewhat off the Strip, as well as in the county around the city.

Some of the most notable casinos involved in downtown gaming are on the Fremont Street Experience which was granted variances to allow bars to be closer together, similar to the Gaslamp Quarter of San Diego.

Conference Highlights

Hospital Infections
Device-Related Infections
Surgical Site Infections
Urinary Tract Infections
Respiratory disorders and Infections
Blood Stream Infections and Clinical Sepsis
Opportunistic infections
Emerging Infectious Diseases
Antibiotics and Antimicrobial Use
Microbial Pathogenesis and Antimicrobial Resistance
Infection Prevention and Control
Microbial Biofilms
Epidemiology and Public Health
Therapeutic Approaches
Vaccines and Immunization
Diagnostic Microbiology and Bioterrorism
Occupational Health hazards and safety
Environmental Microbiology
Medical Microbiology
Pharmaceutical Microbiology
Clinical Studies and Case Reports
Profession of Health Care and Infections Specialists Meeting
Entrepreneurs Investment Meet
Global trends in Nosocomial and Healthcare Acquired Infections

Target Audience:

Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments
Infectious Diseases Associations and related fields of Investigation
Infectious Diseases Researchers, Scientists, Faculties, Students
Laboratory Technicians and Diagnostic Companies
Drug Manufacturing Companies and Industries
Medical Devices Manufacturing Companies
Pharmaceutical Companies and Industries
Health care organizations and societies
Medical Colleges

Market Analysis:

Nosocomial and Healthcare-associated infections (NHAI) are the infections patients can get while receiving medical treatment in a healthcare facility–are a major, yet often preventable, threat to patient safety. Together with health care and public health partners, Centers for Disease Control and Prevention (CDC) is working to bring increased attention to NHAI and prevention. Although significant progress has made in preventing some infection types, there is much more work to be done. On any given day, about one in 25 hospital patients has at least one healthcare-associated infection.

CDC’s annual National and State Healthcare-Associated Infections Progress Report (HAI Progress Report) describes national and state progress in preventing HAIs. Among national acute care hospitals, the most recent report (2014 data, published 2016) found:

50 percent decrease in central line-associated bloodstream infections (CLABSI) between 2008 and 2014
No change in overall catheter-associated urinary tract infections (CAUTI) between 2009 and 2014
- However, there was progress in non-ICU settings between 2009 and 2014, progress in all settings between 2013 and 2014, and even more progress in all settings towards the end of 2014
17 percent decrease in surgical site infections (SSI) related to the 10 select procedures tracked in previous reports
- 17 percent decrease in abdominal hysterectomy SSI between 2008 and 2014
- 2 percent decrease in colon surgery SSI between 2008 and 2014

8 percent decrease in hospital-onset Clostridium difficile (C. difficile) infections between 2011 and 2014
13 percent decrease in hospital-onset methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (bloodstream infections) between 2011 and 2014

The report also includes a national snapshot of HAIs in long-term acute care hospitals (LTACHs) and inpatient rehabilitation facilities (IRFs).

Long-Term Acute Care Hospitals: 9 percent decrease in Central Line-Associated Bloodstream Infections (CLABSI) and an 11 percent decrease in Catheter-Associated Urinary Tract Infections (CAUTIs) between 2013 and 2014
Inpatient Rehabilitation Facilities: 14 percent decrease in CAUTI between 2013 and 2014

In 2014, results of a project known as the HAI Prevalence Survey were published. The Survey described the burden of HAIs in U.S. hospitals, and reported that, in 2011, there were an estimated 722,000 HAIs in U.S. acute care hospitals.

HAI Estimates Occurring in US Acute Care Hospitals, 2011
Major Site of Infection	Estimated No.
Pneumonia	157500
Gastrointestinal Illness	123100
Urinary Tract Infections	93300
Primary Bloodstream Infections	71900
Surgical site infections from any inpatient surgery	157500
Other types of infections	118500
Estimated total number of infections in hospitals	721800

Additionally, about 75,000 patients with NIs died during their hospitalizations. More than half of all HAIs occurred outside of the intensive care unit. Steps can be taken to control and prevent HAIs in a variety of settings. Research shows that when healthcare facilities, care teams, and individual doctors and nurses, are aware of infection problems and take specific steps to prevent them, rates of some targeted HAIs (e.g., CLABSI) can decrease by more than 70 percent. Preventing HAIs is possible, but it will take a conscious effort of everyone–clinicians, healthcare facilities and systems, public health, quality improvement groups, and the federal government–working together toward improving care, protecting patients, and saving lives.

Nosocomial Infection: Devices, Pharmaceuticals, and Environmental Products BCC Research.

This study provides an in-depth analysis and forecast of selected areas of the global Nosocomial and Healthcare associated Infections (NHAI) market. For purposes of this report, NHAI includes hospitals, nursing homes, outpatient surgery centres and dialysis centres. The focus of this report is on selected devices, pharmaceuticals and environmental products currently used or under development for treatment of viral, bacterial and fungal infections.

The global market for selected NHAI treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.

The global hospital acquired infections testing market is poised to grow at a compound annual growth rate (CAGR) of around 19.1% over the next decade to reach approximately $2.75 billion by 2025.

The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.

Estimated cost of treating resistant infections in U.S. health care system is about $21 billion to $34 billion annually

Conference Series invites all the participants from all over the world to attend “International Congress on Nosocomial and Healthcare associated Infections” (NHAI 2017) scheduled during October 02-04, 2017 in Las Vegas, USA. Nosocomial Infections 2017 brings together the global leaders in Nosocomial Infections and Healthcare to present their research at this exclusive scientific program. The Nosocomial Infections conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of infectious diseases, immunology, microbiology, infection prevention and infection control. Nosocomial Infections 2017 Organizing Committee also invites young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions.

Nosocomial Infections (NIs) or Hospital-Acquired Infections (HAIs) are a major complication for professionals of health care to tackle. Every day, NIs results in longer hospital stays, long-term disability, and increasing the resistance of microorganisms to antimicrobials, additional massive costs to health care systems, high costs for patients and their families, and unnecessary deaths. Prevention and infection control is needed to prevent transmission of infectious diseases in all health care settings. Infection prevention and control demands a basic understanding of the epidemiology of diseases, risk factors that increase patient susceptibility to infection, and the practices, procedures and treatments that may result in infections. The risk of acquiring Nosocomial infections is related to the mode of transmission of the infectious agent (e.g. Clostridium difficile -CDI, Surgical Site Infections-SSI, Carbapenem-resistant Enterobacteriacae -CRE, Methicillin-resistant Staphylococcus aureus-MRSA, etc.) and the type of patient-care activity or procedure being performed and the underlying patient’s host defences.

The conference attains significance when we look at the Data and Statistics of Nosocomial Infections (NIs) or Hospital Acquired Infections (HAIs) by Centre for Disease Control and Prevention (CDC) .In 2014, the results of a project known as HAI Prevalence Survey were published. The survey describes the burden of nosocomial infections in US hospitals, and reported that in 2011 there were about 722,000 NIs in US acute care hospitals. In addition, approximately 75,000 patients with NIs died during their hospitalization. More than half of all hospital infections took place outside the intensive care unit.

Who should attend?

Infectious Disease Consultants
Medical Laboratory Supervisors
Internal Medicine Consultants
Infection Control Personnel
Health Care Professionals
Laboratory Technologists
Infection Control Nurses
Patient Safety Managers
Medical Technologists
Clinical Scientists
Epidemiologists
Microbiologists
Bacteriologists
Parasitologists
Pathologists
Mycologists
Pharmacists
Intensivists
Internists
Virologists

Why to attend?

With members from around the world focused on learning about global trends on emerging infectious diseases and its advances in therapeutic and diagnostic market, this is your best opportunity to reach the largest assemblage of participants from the Infectious diseases community. This particular conference conduct presentations, distributes information, conducts meetings with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2 day event. World renowned speakers, the most recent therapeutic and diagnostic techniques, developments, and the Novel technologies and therapeutic measures for Nosocomial infection and Healthcare are hallmarks of this conference.

Targeted Audience

Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments
Infectious Diseases Associations and related fields of Investigation
Infectious Diseases Researchers, Scientists, Faculties, Students
Laboratory Technicians and Diagnostic Companies
Drug Manufacturing Companies and Industries
Medical Devices Manufacturing Companies
Pharmaceutical Companies and Industries
Health care organizations and societies
Medical Colleges

For Scientific Sessions please go through the link: http://nosocomialinfections.conferenceseries.com/call-for-abstracts.php

For Abstract Submission please go through the link: http://nosocomialinfections.conferenceseries.com/abstract-submission.php

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 02-04, 2017
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2	Day 3
Poster Opportunity Closed	Click Here to View

International Congress on Nosocomial and Healthcare Associated Infections October 02-04, 2017 Las Vegas,Nevada,USA

Recommended Global Microbiology Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

NHAI 2017

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues